Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice

@article{Hebb2008Phosphodiesterase1I,
  title={Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice},
  author={Andrea L. O. Hebb and Harold A. Robertson and Eileen M. Denovan‐Wright},
  journal={European Neuropsychopharmacology},
  year={2008},
  volume={18},
  pages={339-363}
}

PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model

Results show that inhibition of PDE10 improves cognition in R6 mice, at least in part through increased GluA1 and CREB phosphorylation, which might be a good therapeutic target to improve cognitive impairment in HD.

Inhibition of phosphodiesterase 10 A attenuates morphine-induced conditioned place preference

Inhibition of PDE10A may have therapeutic potential in the treatment of opioid addiction, according to the results of a study tested on acquisition, expression, and extinction of morphine-induced conditioned place preference.

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

PDE-Is have a positive effect on several aspects of cognition, including information processing, attention, memory, and executive functioning; the most suitable candidates appear to be PDE2-Is or PDE9-Is.

Inhibition of phosphodiesterase10A attenuates morphine-induced conditioned place preference

Inhibition of PDE10A may have therapeutic potential in the treatment of opioid addiction by inhibiting the acquisition and expression of morphine-induced conditioned place preference.

Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.

This review will focus on the contributions of PDEs to the interface between cognitive deficits and neuropsychiatric and neurodegenerative disorders, and it is expected to make for the understanding and discovery that selective PDE inhibitors have the therapeutic potential for cognitive dysfunctions associated with neuro psychological disorders.

References

SHOWING 1-10 OF 71 REFERENCES

Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity

Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.

By enhancing corticostriatal signaling, PDE10A inhibitors have the potential to improve some of the cognitive symptoms of schizophrenia and are consistent with their potential as antipsychotic agents.

Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice.

It is suggested that impaired ATP synthesis and diminished cAMP levels amplify the early HD disease cascade by decreasing CRE-regulated gene transcription and altering energy dependent processes essential to neuronal cell survival.

Animal Model of Schizophrenia

The repeatedPCP treatment impaired NMDA receptor function and decreased levels of spontaneous extracellular glutamate in the prefrontal cortex, indicating that the repeated PCP treatment impairs both pre‐ and postsynaptic glutamate transmissions.

Striking changes in anxiety in Huntington's disease transgenic mice

Effect of sildenafil on anxiety in the plus-maze test in mice.

Results suggest that a nitric oxide-cGMP pathway seems to play an important role in sildenafil-induced anxiogenic-like effect.

Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning

The results indicate that enhancement of cyclic nucleotide signaling by inactivation of PDE1B-mediated cyclicucleotide hydrolysis plays a significant role in dopaminergic function through the DARPP-32 and related transduction pathways.
...